{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:12:12Z","timestamp":1778155932103,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvoice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Voice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jvoice.2026.03.028","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:40:11Z","timestamp":1778154011000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis"],"prefix":"10.1016","author":[{"given":"Mohammed H.","family":"Baali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz A.","family":"Neazy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahaj A.","family":"Altalhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-4008","authenticated-orcid":false,"given":"Sara.A.","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed I.","family":"almohizea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-8378","authenticated-orcid":false,"given":"Manal A.","family":"bukhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvoice.2026.03.028_bib1","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/MOO.0000000000000490","article-title":"Recurrent respiratory papillomatosis: update 2018","volume":"26","author":"Derkay","year":"2018","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib2","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s00405-022-07388-6","article-title":"Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review","volume":"279","author":"Pogoda","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib3","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1097\/MLG.0b013e31816a7135","article-title":"Recurrent respiratory papillomatosis: a review","volume":"118","author":"Derkay","year":"2008","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/000348940611500905","article-title":"Office-based 532-nm pulsed KTP laser treatment of glottal papillomatosis and dysplasia","volume":"115","author":"Zeitels","year":"2006","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/lary.29084","article-title":"Systemic bevacizumab (avastin) for juvenile-onset recurrent respiratory papillomatosis: a systematic review","volume":"131","author":"Ryan","year":"2021","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib6","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1002\/lary.30617","article-title":"Long-term follow-up of parenteral bevacizumab in patients with recurrent respiratory papillomatosis","volume":"133","author":"Ballestas","year":"2023","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib7","first-page":"340","article-title":"Recurrent respiratory papillomatosis: a 2020 perspective","volume":"6","author":"Benedict","year":"2021","journal-title":"Laryngosc\u00a0Investig\u00a0Otolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib8","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1002\/lary.31670","article-title":"A consensus statement on the administration of systemic bevacizumab in patients with recurrent respiratory papillomatosis","volume":"134","author":"Best","year":"2024","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib9","unstructured":"FDA Approves First Immunotherapy for Recurrent Respiratory Papillomatosis. Updated August 14, 2025. \u3008https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-immunotherapy-recurrent-respiratory-papillomatosis\u3009."},{"key":"10.1016\/j.jvoice.2026.03.028_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/lary.70379","article-title":"Recurrent respiratory papillomatosis foundation position statement on the management of adults with RRP","author":"Best","year":"2026","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib11","article-title":"DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1\/2 study assessing efficacy, safety, and immunogenicity of INO-3107","volume":"16","author":"Morrow","year":"2025","journal-title":"Nat\u00a0Commun"},{"key":"10.1016\/j.jvoice.2026.03.028_bib12","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/lary.32416","article-title":"DNA immunotherapy (INO-3107) results in long-term surgery reduction in RRP","volume":"135","author":"Amin","year":"2025","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s40425-019-0603-3","article-title":"Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis","volume":"7","author":"Allen","year":"2019","journal-title":"J Immunotherapy Cancer"},{"key":"10.1016\/j.jvoice.2026.03.028_bib14","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jvoice.2026.03.028_bib15","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Chandler","year":"2019"},{"key":"10.1016\/j.jvoice.2026.03.028_bib16","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst\u00a0Rev"},{"key":"10.1016\/j.jvoice.2026.03.028_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jvoice.2026.03.028_bib18","first-page":"1","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"2","author":"Peterson","year":"2011","journal-title":"Ott: Ott\u00a0Hosp\u00a0Res\u00a0Inst"},{"key":"10.1016\/j.jvoice.2026.03.028_bib19","unstructured":"Lung N.H., Institute B. Quality Assessment Tool for Observational Cohort and Cross-sectional Studies [WWW Document]. URL \u3008https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools\u3009\u00a0(accessed 825 19). 2018."},{"key":"10.1016\/j.jvoice.2026.03.028_bib20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1002\/lary.26662","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey","volume":"127","author":"Best","year":"2017","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib21","first-page":"1912","article-title":"Rapid response to systemic bevacizumab therapy in recurrent respiratory papillomatosis","volume":"8","author":"Mohr","year":"2014","journal-title":"Oncol\u00a0Lett"},{"key":"10.1016\/j.jvoice.2026.03.028_bib22","doi-asserted-by":"crossref","DOI":"10.4046\/trd.2008.65.5.390","article-title":"Efficacy of long-term interferon-alpha therapy in adult patients with recurrent respiratory papillomatosis","volume":"65","author":"Nam","year":"2008","journal-title":"Tuberc Respir Dis"},{"key":"10.1016\/j.jvoice.2026.03.028_bib23","first-page":"223","article-title":"The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma","volume":"29","author":"Young","year":"2015","journal-title":"J\u00a0Voice"},{"issue":"S3","key":"10.1016\/j.jvoice.2026.03.028_bib24","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1007\/s12070-021-02783-7","article-title":"Experience with systemic bevacizumab in advanced juvenile recurrent respiratory papillomatosis","volume":"74","author":"Aggarwal","year":"2022","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib25","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/000348948809700409","article-title":"Alpha-interferon (wellferon) as an adjunct to standard surgical therapy in the management of recurrent respiratory papillomatosis","volume":"97","author":"Benjamin","year":"1988","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"S1","key":"10.1016\/j.jvoice.2026.03.028_bib26","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s12070-011-0456-7","article-title":"Management of adult recurrent respiratory papillomatosis with oral acyclovir following micro laryngeal surgery: a case series","volume":"66","author":"Chaturvedi","year":"2014","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib27","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/hed.27300","article-title":"Aggressive recurrent respiratory papillomatosis: a series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience","volume":"45","author":"Collette","year":"2023","journal-title":"Head Neck"},{"key":"10.1016\/j.jvoice.2026.03.028_bib28","unstructured":"Crockett D.M., Lusk R.P., McCabe B.F. Side Effects And Toxicity of Interferon in the Treatment of Recurrent Respiratory Papillomatosis."},{"key":"10.1016\/j.jvoice.2026.03.028_bib29","doi-asserted-by":"crossref","first-page":"E1926","DOI":"10.1002\/lary.29351","article-title":"Long-term follow-up on systemic bevacizumab treatment in recurrent respiratory papillomatosis","volume":"131","author":"Evers","year":"2021","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib30","unstructured":"Gerein V., Rastorguev E., Gerein J., Pfister H. Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-Up."},{"key":"10.1016\/j.jvoice.2026.03.028_bib31","first-page":"47","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis. A case series","volume":"8","author":"Gregersen","year":"2023","journal-title":"Acta Oto-Laryngol\u00a0Case Rep"},{"key":"10.1016\/j.jvoice.2026.03.028_bib32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJM198808183190704","article-title":"Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial","volume":"319","author":"Healy","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvoice.2026.03.028_bib33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/archotol.1988.01860220097032","article-title":"Randomized surgical adjuvant trial of interferon alfa-n1 in recurrent papillomatosis","volume":"114","author":"Leventhal","year":"1988","journal-title":"Arch\u00a0Otolaryngol\u00a0Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib34","first-page":"435","article-title":"Systemic bevacizumab for pediatric patients with aggressive recurrent respiratory papillomatosis: one single-center experience of eight patients","volume":"8","author":"Liu","year":"2023","journal-title":"Laryngosc\u00a0Investig\u00a0Otolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1258\/0022215042244741","article-title":"Interferon alpha-2b as adjuvant treatment of recurrent respiratory papillomatosis in Cuba: National Programme (1994-1999 report)","volume":"118","author":"Nodarse-Cun\u00cd","year":"2004","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/019459988409200403","article-title":"Interferon therapy in juvenile laryngeal papillomatosis","volume":"92","author":"Lundquist","year":"1984","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/000348941112000103","article-title":"Initial experience using propranolol as an adjunctive treatment in children with aggressive recurrent respiratory papillomatosis","volume":"120","author":"Maturo","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib38","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1002\/lary.30749","article-title":"Interim results of a phase 1\/2 open-label study of INO-3107 for HPV-6 and\/or HPV-11\u2013associated recurrent respiratory papillomatosis","volume":"133","author":"Mau","year":"2023","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1186\/s12879-018-3260-0","article-title":"HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis","volume":"18","author":"Mauz","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jvoice.2026.03.028_bib40","first-page":"962","article-title":"A retrospective case-control analysis of the efficacy of Gardasil\u00ae vaccination in 28 patients with recurrent respiratory papillomatosis of the larynx","volume":"43","author":"Milner","year":"2018","journal-title":"Clin\u00a0Otolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0145561318823311","article-title":"Postoperative systemic acyclovir in juvenile-onset recurrent respiratory papillomatosis: the outcome","volume":"98","author":"Mitra","year":"2019","journal-title":"Ear Nose Throat J"},{"key":"10.1016\/j.jvoice.2026.03.028_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1177\/00034894211007227","article-title":"Initial experience treating HPV-related laryngeal diseases with oral brincidofovir: a pilot study","volume":"130","author":"Richardson","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib43","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/lary.30021","article-title":"Systemic bevacizumab treatment for recurrent respiratory papillomatosis: long-term follow-up","volume":"132","author":"Ruiz","year":"2022","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib44","article-title":"Healthcare spending and systemic bevacizumab for recurrent respiratory papillomatosis","author":"Schuman","year":"2024","journal-title":"J\u00a0Voice"},{"key":"10.1016\/j.jvoice.2026.03.028_bib45","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/lary.31387","article-title":"Systemic bevacizumab for recurrent respiratory papillomatosis: a single institution's experience","volume":"134","author":"So","year":"2024","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/lary.29133","article-title":"Parenteral bevacizumab for the treatment of severe respiratory papillomatosis in an adult population","volume":"131","author":"Tkaczuk","year":"2021","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib47","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s00405-023-08430-x","article-title":"Systemic bevacizumab for treatment of recurrent respiratory papillomatosis","volume":"281","author":"Zhao","year":"2024","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib48","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S2213-2600(24)00368-0","article-title":"PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1\/2 clinical trial","volume":"13","author":"Norberg","year":"2025","journal-title":"The Lancet Respiratory Medicine"},{"key":"10.1016\/j.jvoice.2026.03.028_bib49","article-title":"Disease control and voice outcomes following treatment with PRGN-2012 in adults with recurrent respiratory papillomatosis","author":"Kaskas","year":"2025","journal-title":"J\u00a0Voice"},{"key":"10.1016\/j.jvoice.2026.03.028_bib50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/S0022215100136667","article-title":"Use of interferon-\u03b1 in laryngeal papillomatosis: eight years of the Cuban national programme","volume":"111","author":"Deunas","year":"1997","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib51","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(20)32667-2","article-title":"Male infertility","volume":"397","author":"Agarwal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jvoice.2026.03.028_bib52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.otohns.2004.09.035","article-title":"Incidence, age at onset, and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience","volume":"132","author":"Gerein","year":"2005","journal-title":"Otolaryngol\u2013Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/000348948709600524","article-title":"Treatment of recurrent respiratory papillomatosis with interferon","volume":"96","author":"Crockett","year":"1987","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib54","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ohn.629","article-title":"Factors associated with iatrogenic laryngeal injury in recurrent respiratory papillomatosis","volume":"170","author":"So","year":"2024","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib55","series-title":"551 Consistent and Rapid Clinical Benefit from Systematic Bevacizumab-bvzr in Adult Patients with HPV-Associated Recurrent Respiratory Papillomatosis","author":"Norberg","year":"2025"},{"key":"10.1016\/j.jvoice.2026.03.028_bib56","first-page":"1023","article-title":"Long-term response of recurrent respiratory papillomatosis to interferon alfa therapy","volume":"99","author":"Leventhal","year":"1989","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijporl.2019.109815","article-title":"Laryngeal sequelae secondary to surgical treatment for recurrent respiratory papillomatosis in children","volume":"130","author":"Scatolini","year":"2020","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2710.2009.01150.x","article-title":"Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics","volume":"36","author":"Pomfret","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jvoice.2026.03.028_bib59","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jvoice.2026.03.028_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/000348940711600302","article-title":"Immunocompetency in children with recurrent respiratory papillomatosis: prospective study","volume":"116","author":"Stern","year":"2007","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.jvoice.2026.03.028_bib61","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archotol.132.7.711","article-title":"Longitudinal measures of human papillomavirus 6 and 11 viral loads and antibody response in children with recurrent respiratory papillomatosis","volume":"132","author":"Maloney","year":"2006","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jvoice.2026.03.028_bib62","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jvoice.2026.03.028_bib63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1288\/00005537-199006000-00016","article-title":"HPV DNA typing of adult-onset respiratory papillomatosis","volume":"100","author":"Duggan","year":"1990","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.jvoice.2026.03.028_bib64","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa1003509","article-title":"Oral acyclovir suppression and neurodevelopment after neonatal herpes","volume":"365","author":"Kimberlin","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Journal of Voice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0892199726001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:40:19Z","timestamp":1778154019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0892199726001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":64,"alternative-id":["S0892199726001463"],"URL":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.03.028","relation":{},"ISSN":["0892-1997"],"issn-type":[{"value":"0892-1997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Voice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvoice.2026.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Voice Foundation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}